All In MedTech

FDA Clearance Tracker · P190023-S029

Navitor™ TAVI System with Vision Technology

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jun 3, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jun 3, 2026

Approved

Time to decision

180 days

Received Dec 5, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P190023-S029
Device name
Navitor™ TAVI System with Vision Technology
Applicant location
St. Paul, MN
Received
Dec 5, 2025
Decided
Jun 3, 2026
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - PAS
Original approval
P190023

Device type

Device class
Class III

Every decision under product code NPT

FDA's approval statement

As written in FDA's record.

approval for modifications to the Instructions for Use to reflect the 5-year findings of the Post-Approval Study (PAS) Report submitted for the long term follow-up of the Portico TAVI System prospective cohort study

Source documents

Other decisions for ABBOTT MEDICAL

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.